LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.
LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.